These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 18196976

  • 1. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
    Selvendiran K, Bratasz A, Tong L, Ignarro LJ, Kuppusamy P.
    Cell Cycle; 2008 Jan 01; 7(1):81-8. PubMed ID: 18196976
    [Abstract] [Full Text] [Related]

  • 2. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
    Bratasz A, Selvendiran K, Wasowicz T, Bobko A, Khramtsov VV, Ignarro LJ, Kuppusamy P.
    J Transl Med; 2008 Feb 26; 6():9. PubMed ID: 18302761
    [Abstract] [Full Text] [Related]

  • 3. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
    Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.
    Cancer Biol Ther; 2011 Nov 01; 12(9):837-45. PubMed ID: 21885917
    [Abstract] [Full Text] [Related]

  • 4. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, Ingersoll SB, Turkson J.
    Oncogene; 2012 May 03; 31(18):2309-22. PubMed ID: 21909139
    [Abstract] [Full Text] [Related]

  • 5. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin.
    Bratasz A, Weir NM, Parinandi NL, Zweier JL, Sridhar R, Ignarro LJ, Kuppusamy P.
    Proc Natl Acad Sci U S A; 2006 Mar 07; 103(10):3914-9. PubMed ID: 16497833
    [Abstract] [Full Text] [Related]

  • 6. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
    Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY, Liu L, Deng HX, Li J, Nie CL, Wei YQ.
    Mol Med; 2011 Mar 07; 17(11-12):1262-74. PubMed ID: 21863213
    [Abstract] [Full Text] [Related]

  • 7. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F, Ding W, Wang J, Xia X, Li F, Hu W, Lu Y, Wang S, Zhou J, Ma D, Gao Q.
    Cancer Lett; 2013 Dec 01; 341(2):231-9. PubMed ID: 23962558
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z, Hong Z, Gao Q, Chen C, Hao Z, Ji T, Hu W, Yan Y, Feng J, Liao S, Wu P, Wang D, Wang S, Zhou J, Ma D.
    Hum Gene Ther; 2012 Jan 01; 23(1):32-45. PubMed ID: 21875334
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J, Shi HR, Ren F, Wang JL, Wu QH, Li X, Zhang RT.
    BMC Cancer; 2017 Dec 14; 17(1):851. PubMed ID: 29241458
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X, Shen H, Yin X, Long L, Chen X, Feng F, Liu Y, Zhao P, Xu Y, Li M, Xu W, Li Y.
    Oncotarget; 2017 Jun 13; 8(24):39154-39166. PubMed ID: 28388577
    [Abstract] [Full Text] [Related]

  • 20. TRIAP1 Inhibition Activates the Cytochrome c/Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin.
    Zhang TM.
    Chemotherapy; 2019 Jun 13; 64(3):119-128. PubMed ID: 31661694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.